Geneius Biotechnology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Geneius Biotechnology is a private, pre-revenue biotech based in San Diego, advancing a novel platform of non-genetically engineered, autologous T-cell therapies for cancer. Its proprietary Targeted DiversiTy™ and SMAR-T™ manufacturing platform aims to produce T cells with superior killing, homing, and duration against solid and liquid tumors, starting with EBV+ cancers. The company highlights compelling academic proof-of-concept data, a scalable manufacturing process, and a potential cost and accessibility advantage over current CAR-T therapies as key differentiators as it moves toward initial clinical trials.

Oncology

Technology Platform

Targeted DiversiTy™ platform for ex vivo re-education of autologous T cells without genetic engineering, coupled with the SMAR-T™ GMP manufacturing process.

Opportunities

The primary opportunity lies in addressing the vast unmet need in solid tumor immunotherapy, where current CAR-T therapies have failed.

Success could also disrupt the cell therapy market by offering a potentially safer, more affordable, and more accessible treatment that can be administered in community oncology settings, significantly expanding patient reach.

Risk Factors

Key risks include the failure to replicate compelling academic proof-of-concept data in controlled clinical trials, potential challenges in scaling the proprietary manufacturing process consistently, and intense competition from other next-generation cell therapy modalities also targeting solid tumors.

As a pre-revenue private company, it also faces significant funding and execution risk.

Competitive Landscape

Geneius competes in the adoptive cell therapy space, directly contrasting its non-genetically engineered approach against dominant CAR-T and emerging TCR-T therapies. Its key differentiators are targeting solid tumors, a favorable safety profile, and lower cost. However, it faces competition from well-funded companies developing engineered and non-engineered T-cell therapies, tumor-infiltrating lymphocytes (TILs), and other immunotherapies for the same indications.

More companies in Cell & Gene Therapy →More companies in United States →